Evidence map›Paper›PMID 33901262›Full record

ArticlePLoS pathogens2021

Origin and evolution of the zinc finger antiviral protein.

Daniel Gonçalves-Carneiro, Matthew A Takata, Heley Ong, Amanda Shilton, Paul D Bieniasz

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Host ZAP activity correlates with the levels of CpG suppression in primate lentiviruses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Modulation of host gene expression by the zinc finger antiviral protein.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Human Riboviruses: A Comprehensive Study.Journal of molecular evolution · 2025
    Review
  13. Article
  14. Article
  15. A minimal complex of KHNYN and zinc-finger antiviral protein binds and degrades single-stranded RNA.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Article
  17. Article
  18. Antiviral Effects of Avian Interferon-Stimulated Genes.Animals : an open access journal from MDPI · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Daniel Gonçalves-CarneiroLaboratory of Retrovirology, The Rockefeller University, New York City, New York, United States of America.ORCID 0000-0002-9333-1540
Matthew A TakataLaboratory of Retrovirology, The Rockefeller University, New York City, New York, United States of America.
Heley OngLaboratory of Retrovirology, The Rockefeller University, New York City, New York, United States of America.ORCID 0000-0002-9651-3892
Amanda ShiltonLaboratory of Retrovirology, The Rockefeller University, New York City, New York, United States of America.ORCID 0000-0002-9083-8696
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York City, New York, United States of America.ORCID 0000-0002-2368-3719
Rockefeller University · USHoward Hughes Medical Institute · US

Funding

The Center for HIV RNA Studies (CRNA)U54AI150470 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUMMERS, MICHAEL FINLEY · 2019 to 2021
$15.1M
RNA Protein interactions in HIV-1 replicationR01AI050111 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2001 to 2021
$7.9M
NIAID NIH HHS R01 AI050111NIAID NIH HHS U54 AI150470
6 · The paper itself

Abstract

The human zinc finger antiviral protein (ZAP) recognizes RNA by binding to CpG dinucleotides. Mammalian transcriptomes are CpG-poor, and ZAP may have evolved to exploit this feature to specifically target non-self viral RNA. Phylogenetic analyses reveal that ZAP and its paralogue PARP12 share an ancestral gene that arose prior to extensive eukaryote divergence, and the ZAP lineage diverged from the PARP12 lineage in tetrapods. Notably, the CpG content of modern eukaryote genomes varies widely, and ZAP-like genes arose subsequent to the emergence of CpG-suppression in vertebrates. Human PARP12 exhibited no antiviral activity against wild type and CpG-enriched HIV-1, but ZAP proteins from several tetrapods had antiviral activity when expressed in human cells. In some cases, ZAP antiviral activity required a TRIM25 protein from the same or related species, suggesting functional co-evolution of these genes. Indeed, a hypervariable sequence in the N-terminal domain of ZAP contributed to species-specific TRIM25 dependence in antiviral activity assays. Crosslinking immunoprecipitation coupled with RNA sequencing revealed that ZAP proteins from human, mouse, bat and alligator exhibit a high degree of CpG-specificity, while some avian ZAP proteins appear more promiscuous. Together, these data suggest that the CpG- rich RNA directed antiviral activity of ZAP-related proteins arose in tetrapods, subsequent to the onset of CpG suppression in certain eukaryote lineages, with subsequent species-specific adaptation of cofactor requirements and RNA target specificity.

Indexed as

Antiviral AgentsEvolution, MolecularAlligators and CrocodilesAnimalsCells, CulturedChickensDucksEaglesFinchesHEK293 CellsHumansMicePhylogenyRNA-Binding ProteinsTranscription FactorsTripartite Motif ProteinsAntiviral AgentsRNA-Binding ProteinsTranscription FactorsTRIM25 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesZC3HAV1 protein, human

Identifiers

PMID33901262
PMCPMC8102003
OpenAlexW3158085424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.